Tibotec was a biopharmaceutical company based in Belgium.
History
Tibotec was acquired by Johnson & Johnson in April 2002.[1]
Tibotec provided funding for HIV treatment clinical trials at the Infectious Diseases Institute in Kampala, Uganda, including trials involving David Boulware.[2][3]
The company was renamed to Janssen Therapeutics in June 2011.[4]
External links
Johnson & Johnson to Acquire Tibotec-Virco. (2002, March 22). Johnson & Johnson. https://web.archive.org/web/20020608123005/http://www.investor.jnj.com/ReleaseDetail.cfm?ReleaseID=75177 ↩︎
Clinical Research at the Infectious Diseases Institute. The Global Health Network; Infectious Diseases Institute. Retrieved May 17, 2023, from https://web.archive.org/web/20230517060735/https://media.tghn.org/site_finder/sites/documents/Clinical_Research_at_IDI.pdf ↩︎
Schmickle, S. (2008, November 13). University of Minnesota doctors battle AIDS in Uganda. MinnPost. http://archive.today/2010.06.23-113510/http://www.minnpost.com/stories/2008/11/13/4537/university_of_minnesota_doctors_battle_aids_in_uganda ↩︎
Van Houten, P. (2011, June 22). Tibotec Therapeutics Becomes Janssen Therapeutics, Part Of The Janssen Pharmaceutical Companies. Johnson & Johnson. http://archive.today/2023.05.17-061755/https://www.jnj.com/media-center/press-releases/tibotec-therapeutics-becomes-janssen-therapeutics-part-of-the-janssen-pharmaceutical-companies ↩︎
